Pre-EclampsiaPOP-HTNCT04273854
Physician Optimised Post-partum Hypertension Treatment Trial
A study testing OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app® in people with Pre-Eclampsia and Gestational Hypertension, run by University of Oxford at 2 sites in United Kingdom.
Trial summary
It has been shown in a pilot randomised controlled study [SNAP-HT [4]; REC 14/SC/1316] that blood pressure self-management during the post-partum period after hypertensive pregnancies, results in lower blood pressure after six months; even when medication has been stopped. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Pre-Eclampsia, Gestational Hypertension
- What is being tested?
- OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 21 Feb 2020to 1 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant is willing and able to give informed consent for participation in the trial.
- Female, aged 18 years or above.
- Clinician confirmed diagnosis of either gestational hypertension or pre-eclampsia defined by NICE NG 133
- Requiring anti-hypertensive medication at the point of discharge from secondary care.
- Participant has clinically acceptable laboratory results and clinical course post-partum with no other adverse complicating factor requiring prolonged admission post-partum that would make participation unfeasible as judged by the CI. Examples would include stroke sequalae, ongoing DIC, the baby/babies requiring prolonged NICU/SCBU admission of >1 week.
- In the Investigator's opinion, is able and willing to comply with all trial requirements including ownership of a 'Smart-phone/Tablet' and willing to use the smart-phone app if randomised to that arm.
- Sufficient competence in English Language to follow the app instructions and partake in the study, as judged by the CI
Who cannot join
- Significant renal or hepatic impairment that would affect safe medication titration and adjustment as part of the trial, as deemed by the Investigator.
- Scheduled elective surgery (excluding caesarean sections) or other procedures requiring general anaesthesia during the trial.
- Participant with life expectancy of less than 6 months.
- Any other significant disease or disorder, which, in the opinion of the Investigator, may either, put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
- An absolute contra-indication to MRI (as per MRI safety questionnaire)
Show all 10Show fewer
- Women with pre-existing hypertension will be excluded, as this is a separate pathology that would affect the efficacy of the study intervention and affect the primary and secondary outcomes of the study.
- Additional exclusion criteria specific to the Gadolinium sub-study are:
- Breast feeding,
- eGFR <30ml/minute.
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Oxford University Hospitals NHS Foundation Trust
Oxford, Oxfordhsire, OX3 9DU
Cardiovascular Clinical Research Facility, Dept of Cardiovascular Medicine, University of Oxford
Oxford, Oxfordshire, OX3 9DU
About this study
It has been shown in a pilot randomised controlled study [SNAP-HT [4]; REC 14/SC/1316] that blood pressure self-management during the post-partum period after hypertensive pregnancies, results in lower blood pressure after six months; even when medication has been stopped. The team now want to assess whether this blood pressure reduction can be reproduced in a larger, randomised, study (data analysis blinded) and whether the blood pressure lowering has additional benefits in terms of other cardiovascular and cerebrovascular changes known to occur in women who have had a hypertensive pregnancy. The investigators therefore plan to run a trial of self-management in the post-partum period, using updated Blue-tooth® enabled blood pressure monitoring coupled to physician-assisted dose titration to further advance the self-management aspect of the intervention. The physicians will be specialist clinicians who form part of the research team. The investigators will measure additional structural and functional end organ differences, using magnetic resonance imaging of the brain and heart as well as echocardiography and retinal imaging. This will provide insight into the impact of post-partum blood pressure control on the maternal cardiovascular system and how this associates with blood pressure changes. Together, these studies will help refine future intervention strategies in this cohort of patients.
Read the detailed description
Summary of the Design ---------------------- The trial is a single centre, single blinded (the investigators will be unaware of which group the participants are allocated to), and randomised controlled study i.e. the group participants are put is allocated by chance. The study focuses on women who develop hypertensive disorders of pregnancy, which require ongoing treatment for blood pressure after birth at the time of discharge. These women will be randomised to one of two treatment arms: either usual care by GP/mid-wife/other NHS providers, or self -management of blood pressure. Women will be recruited from the John Radcliffe Hospital and this study will investigate the effectiveness of post-partum physician assisted self-management of blood pressure vs standard care over the first 6 (up to 9) months post-partum.
Trial Setting and participant profile
------------------------------------ The investigators aim to recruit 200 participants, of which 100 will be randomised to the intervention arm and 100 to the control arm. The intervention arm will comprise tele-monitored (remote) home blood pressure monitoring (including periods of home 24hr blood pressure monitoring) coupled to doctors overseeing medication self-management remotely. The control arm will receive 'standard' levels of NHS care from their GP and midwives and health visitors. All participants will be recruited from the Oxford Women's Centre at the John Radcliffe Hospital, which sees approximately 25 patients per month with hypertensive pregnancies (demonstrated in a local audit).
Trial participants --------------------- All participants will be females of childbearing age >18 years of age. Inclusion in the trial will require a clinician confirmed diagnosis of either gestational hypertension or pre-eclampsia as defined by NICE's latest guideline for this condition (NG 133), and the women must still require anti-hypertensive medication to control their blood pressure at the time of planned discharge.
Summary of the study visits
-------------------------- A flow chart of the proposed study visits can be seen in the protocol in section 9.7 and in appendix A of the protocol, which illustrates more clearly this textual description . The expected duration of participant involvement will be 6 (up to 9) months from enrolment to study completion and participants will be asked to attend four study visits after their pre-screening and enrolment: baseline, at 1 week, at 6 weeks and at 6-9 months. Although this study will only involve the four visits described above (outlined in appendix A) currently, further contact may be planned over the next 10 years to allow longitudinal follow up of this cohort. Details of the follow-up visits will be defined closer to the time and REC approval will be sought for any amendment/extension to this study to allow future contact. Additional consent will be sought from the participants to ensure they are happy to continue taking part.
Details of the study visits and procedures:
----------------------------------------- Both groups receive the same number of study visits, 4 visits for all participants.
Visit 1 (90 minutes) will take place in the first days after giving birth whilst participants remain on the post-natal ward in the Women's centre. The team will measure blood pressure, take some simple measurements e.g. weight, waist and hip circumference and scan their hearts (using ultra-sound just like they had of their babies). The team will then review the medical notes and blood tests and provide a questionnaire about lifestyle and diet, which can be completed later to shorten the visit. At the end of visit 1 participants will either be allocated to the intervention group or the control group. If allocated to the intervention group a separate member of the team will come and provide the participant with the blood pressure monitor (an OMRON EVOLV®) used for home monitoring. This team member will register and install the app on the participant's smartphone/tablet and teach the participant how to use it. They will therefore have plenty of time to practice with it whilst still in hospital.
Visits 2 and 3 (30 minutes) take place at weeks 1 and 6 weeks after discharge respectively and are to measure blood pressure, take some simple measurements e.g. waist, left arm and hip circumference, and to complete a brief questionnaire. These will be offered as a home visit, or as a visit to the Cardiovascular Clinical Research Facility (CCRF) at the John Radcliffe Hospital, depending on the women's preference, although based on prior experience it is expected most women will opt for home visits at this busy time in their lives. At the end of Visit 3 (week 6) there will be a 24 hour blood pressure monitor fitted, programmed to be silent to minimise disruption to the mum and the baby and the women will be provided with a stamped, addressed envelopes to post it back to CCRF. At the end of this visit, the team will run through the additional PIS relevant to the 4th visit again. This will allow participants to ask any questions about the longer final study visit up at the hospital, as the investigators are aware there is a lot to take in on the PIS and additional information sheet at the time of enrolment. The team will also call to discuss any further questions and plan child care for this longer visit in advance a few weeks prior to the 4th visit described below.
At 6-9 months there will be a slightly longer visit to CCRF in the John Radcliffe Hospital. Visit 4 (up to 4 hours) will involve measuring blood pressure again, doing another scan of the heart by ultra-sound, doing an MRI (magnet scan) of the heart and brain, and taking a blood test. There will also be a few other simple tests (not absolutely mandatory) but which are more exploratory secondary outcome measures for the study. These include: taking photos of the blood vessels in the back of the eye (retinal imaging, like an optician does), and doing some gentle exercise on a bike (akin to walking up a hill at a fast pace) during which the heart will be scanned to assess its response to exercise.
Each procedure that a participant will be asked to undergo during this study is summarised below in a little more detail: 1. Bed-side blood pressure measurement (10 minutes) Three blood pressure readings will be taken at intervals of 1 minute from the left arm using an automated blood pressure monitor (unless medical reason means the left arm cannot be used). This will require sitting at rest for 5 minutes prior to doing any measurements.
- Echocardiogram scan (15 minutes) The team will perform an ultrasound (echocardiogram/echo) of the heart. This is a safe and painless procedure that takes 15 minutes. The Participant will be asked to lie on a couch on theirleft side. A probe is placed on the chest and lubricating jelly is used so the probe makes good contact with the skin. Ultrasound waves then create images of the heart on the scanner monitor. A female sonographer/scanner will be provided wherever possible and if not available, a female chaperone will be provided.
- Vicorder® (Vascular Measures and Central Blood Pressures, 10 minutes): This involves lying flat on a cough and having two blood pressure cuffs fitted, one to the right arm and one around the right thigh. These are inflated and deflated three times at short intervals to acquire the readings. It is completely safe and painless.
- Lifestyle and physical activity questionnaire (25 minutes): The questionnaire combines validated questionnaires taken from previous studies. Information will be collected on factors that affect blood pressure including: smoking frequency, alcohol and salt intake, exercise and family history. Questionnaires can be completed either during a study visit or at a later date and posted back to the study team (prepaid envelopes will be provided).
- EQ-5D-5L Quality of Life questionnaire (5 minutes): Participants will be provided with an EQ-5D-5L questionnaire, which is a widely used and validated way of assessing quality of life at a set time-point. A trained study investigator will run through the structured questionnaire during the visit with the participant.
- MRI Heart and Brain (1 hour including break) The MRI scanner is shaped like a polo mint, the hole inside measuring about 60 centimetres wide. MRI is safe and non-invasive and does not involve any ionising radiation (x-rays). However, because they use a large magnet to work, MRI scans are not suitable for everybody. Because of this, participants will be asked pre-screening safety questions to help determine if participants are able to take part. More detail about the MRI scan is provided on the additional information sheet given to participants before the 4th study visit. This additional information sheet also provides more detail about the optional sub-study of having gadolinium given (a commonly used contrast drug for MRI) to acquire an extra few images in those women who are no longer breast-feeding at that time-point. Additional consent will be sought and obtained for this sub-study prior to the MRI scan being performed.
- Blood sampling (10 minutes) Blood samples will be collected (about 5 tablespoons (25mls) of blood). More detail is contained in the additional participant additional information sheet.
- Fitting of a home blood pressure monitor (5 minutes, to be worn for 24 hours) and activity monitor (5 minutes, to be worn for 7 days and nights) The monitor consists of a blood pressure cuff, which will be fitted on the left arm (right if a specific medical reason precludes use of the left). A small bag will also be provided that is worn around the waist or shoulders, in which the blood pressure monitor is placed. Participants will be shown how to re-attach the monitor e.g. after a bath or shower or should it fall off. The BP monitor will automatically inflate hourly during the day and every other hour at night to minimise inconvenience at this busy time in their lives. Participants will be asked to wear the blood pressure monitor for 24 hours and to keep a brief blood pressure monitoring diary and information sheet to detail time participants went to sleep/awoke and any periods of cardiovascular activity such as running for the bus/cycling to work. A stamped addressed envelope will be provided to return the device after use. The activity monitor is waterproof and shock-proof and will be worn continually on the wrist for one week and again a stamped addressed envelope will be provided to return the device after use.
- Retinal imaging (10 minutes) Photos will be taken of the back of the eyes just like at an optician. More information about this is provided on the additional PIS for the 4th study visit. To help keep personal information confidential, images will be 'de-identified' and assigned a study code. However, retinal images are unique so they can never be completely anonymous.
- Cardiopulmonary Exercise Testing (CPET) with exercise echo (30 minutes) This involves gentle cycling on a stationary bicycle and doing a short ultrasound (echocardiogram) of the heart whilst exercising. There will be real-time measurement of heart rate and blood pressure. More information about this is provided on the Additional PIS.
- Laser Speckle Tracking/Iontophoresis (15 minutes): this is an optional measure investigators will offer to 24 participants in each group of the trial. This will take an additional 15 minutes and is done twice; once at the baseline and once at the final/4th study visit in the 48 who agree. Participants will be asked to refrain from consuming caffeine (coffee, soft drinks, chocolate, etc.) for 4 hours prior to the forearm blood flow measurements. In this portion of the study, participants lay still in a bed. Two probes will be attached to the inner surface of the forearm. A special camera will be used to visualise blood flow in the skin of the forearm, which involves shining a red light on the skin. The investigators will use the probes to apply harmless solutions to the skin, while measuring the changes in the blood flow with the red light. This procedure causes no pain or discomfort.
The Intervention itself
------------------------- This next section only applies to participants in the intervention group and an additional intervention group information sheet will be provided for the participants allocated/randomised to this group in a written paper document as well as the information being available on the app and the study website. Women in this group will be asked to start measuring their blood pressure on the day of discharge from hospital using the OMRON EVOLV® monitor provided. This will mean taking 2 readings, 1 minute apart every morning after discharge. They will be asked to do this every morning, until they have had 5 consecutive days with blood pressure readings in the normal range (off medication). It is anticipated this will take 2-3 weeks following discharge based on our experience in our pilot study [SNAP-HT; REC 14/SC/1316].
After measuring the blood pressure, they will open up the POP-HT app on their smartphone/tablet, confirm it was them that took the blood pressure readings and click 'SYNC'. The app will then 'synchronise' with the OMRON EVOLV® monitor to upload the reading to the app and the secure study website hosted on the hospital's secure intranet (not the internet).
The smartphone/tablet will notify the participant if the readings are too high, too low or in the normal range. If they are high or low the app will ask them to repeat one more reading. If the reading is still high or low then the app will notify the participant and the specialist study doctors. The participant can then opt to receive a call from the study doctors to help adjust their own medication or they can choose see their own GP/mid-wife (further detailed information about this is available in the self-management information sheet).
Once a participant has 5 days in a row with readings in the normal range (off medication) they will be sent a notification/message reading "Thank you. Your blood pressure readings have all been normal since stopping treatment. Please change to once weekly readings for the remainder of the study." This will be until 6 months after the delivery of their baby/babies. The reason for the longer period of weekly monitoring is to ensure they do not have a late rise in your blood-pressure readings that requires further treatment.
- Conditions
- Pre-Eclampsia, Gestational Hypertension
- Being tested
- OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®
- Medical subject headings
- Pre-Eclampsia, Hypertension, Pregnancy-Induced
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®Device
The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. Receives: Device: OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app® |
| Control | No intervention | The control arm will be managed as per usual NHS led care with assessment by their own health care professionals and adjustment of their medications as is needed. The BP of this group will be monitored and recorded at the same time-points and in the same manner as the intervention arm as will all other secondary outcome measures. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diastolic Blood pressure (BP)
24 hour average diastolic BP measured by 24 hour ambulatory BP monitoring (ABPM)
Measured: 6 months post-partum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2020
- Study start21 Feb 2020
- Primary completion1 Apr 2022 (estimated)
- Study completion1 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Pre-EclampsiaStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Collaborators
- British Heart Foundation
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04273854
- Sponsor's protocol ID
- 273353
- Other IDs
- FS/19/7/34148
- Acronym
- POP-HT
- Status last verified
- Oct 2021
- First submitted
- 29 Jan 2020
- Last updated
- 22 Oct 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be made available, under certain circumstances, following data lock upon request to the study PI.
Publications
Cutler HR, Hanssen H, Hauser C, Streese L, Sattwika PD, Kitt J, McCourt A, Suriano K, Kenworthy Y, Frost A, Krasner S, Lewandowski AJ, Lapidaire W, Leeson P. Retinal Vascular Caliber: 6 to 12 Months and 15 to 25 Years Following Hypertensive Pregnancy. Hypertension. 2026 Aug;83(8):e27171. doi: 10.1161/HYPERTENSIONAHA.126.27171. Epub 2026 Jun 17.
PubMed 42305089Lapidaire W, Kitt J, Krasner S, Bateman PA, Cutler HR, Barr L, Frost A, Tucker K, Suriano K, Kenworthy Y, Milner G, Lacharie M, Mills R, Roman C, Mackillop L, Aye C, Cairns A, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Brain Volumes After Hypertensive Pregnancy and Postpartum Blood Pressure Management: A POP-HT Randomized Clinical Trial Imaging Substudy. JAMA Neurol. 2026 Feb 1;83(2):137-144. doi: 10.1001/jamaneurol.2025.5145.
PubMed 41490362Kitt J, Biasiolli L, Krasner S, Bateman PA, Cutler HR, Barr LC, Frost A, Tucker KL, Suriano K, Kenworthy Y, Lapidaire W, Lacharie M, Mills R, Roman C, Mackillop L, Aye CYL, Cairns AE, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Impact of Blood Pressure Self-Management on Vascular Remodeling After Hypertensive Pregnancy. Hypertension. 2025 Nov;82(11):1938-1947. doi: 10.1161/HYPERTENSIONAHA.125.24854. Epub 2025 Sep 4.
PubMed 40905148Cutler HR, Kitt J, Sattwika PD, Finnigan LEM, Estevez-Fernandez A, Kenworthy Y, Suriano K, Frost A, Krasner S, Johnson C, McCourt A, Mills R, Tucker K, Cairns A, Roman C, Aye C, Mackillop L, Thilaganathan B, Chappell LC, Raman B, Lewandowski AJ, Lapidaire W, Leeson P. Subclinical Postpartum Renal Structure After Hypertensive Pregnancy Disorders. Hypertension. 2025 Nov;82(11):1948-1958. doi: 10.1161/HYPERTENSIONAHA.125.25130. Epub 2025 Aug 31.
PubMed 40886083Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman PA, Suriano K, Kenworthy Y, McCourt A, Woodward W, Lapidaire W, Lacharie M, Santos M, Roman C, Mackillop L, Delles C, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial. JAMA. 2023 Nov 28;330(20):1991-1999. doi: 10.1001/jama.2023.21523.
PubMed 37950919Kitt J, Krasner S, Barr L, Frost A, Tucker K, Bateman PA, Suriano K, Kenworthy Y, Lapidaire W, Lacharie M, Mills R, Roman C, Mackillop L, Cairns A, Aye C, Ferreira V, Piechnik S, Lukaschuk E, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Substudy. Circulation. 2024 Feb 13;149(7):529-541. doi: 10.1161/CIRCULATIONAHA.123.067597. Epub 2023 Nov 11.
PubMed 37950907Kitt J, Frost A, Mollison J, Tucker KL, Suriano K, Kenworthy Y, McCourt A, Woodward W, Tan C, Lapidaire W, Mills R, Lacharie M, Tunnicliffe EM, Raman B, Santos M, Roman C, Hanssen H, Mackillop L, Cairns A, Thilaganathan B, Chappell L, Aye C, Lewandowski AJ, McManus RJ, Leeson P. Postpartum blood pressure self-management following hypertensive pregnancy: protocol of the Physician Optimised Post-partum Hypertension Treatment (POP-HT) trial. BMJ Open. 2022 Feb 23;12(2):e051180. doi: 10.1136/bmjopen-2021-051180.
PubMed 35197335
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physician Optimised Post-partum Hypertension Treatment Trial
- ClinicalTrials.gov ID
- NCT04273854
- Acronym / sponsor ID
- POP-HT / 273353
- Conditions
- Pre-Eclampsia, Gestational Hypertension
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Collaborators
- British Heart Foundation
- Study start
- 21 Feb 2020 (actual)
- Primary completion
- 1 Apr 2022 (estimated)
- Study completion
- 1 Dec 2030 (estimated)
- First posted
- 18 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It has been shown in a pilot randomised controlled study [SNAP-HT [4]; REC 14/SC/1316] that blood pressure self-management during the post-partum period after hypertensive pregnancies, results in lower blood pressure after six months; even when medication has been stopped. The team now want to assess whether this blood pressure reduction can be reproduced in a larger, randomised, study (data analysis blinded) and whether the blood pressure lowering has additional benefits in terms of other cardiovascular and cerebrovascular changes known to occur in women who have had a hypertensive pregnancy. The investigators therefore plan to run a trial of self-management in the post-partum period, using updated Blue-tooth® enabled blood pressure monitoring coupled to physician-assisted dose titration to further advance the self-management aspect of the intervention. The physicians will be specialist clinicians who form part of the research team. The investigators will measure additional structural and functional end organ differences, using magnetic resonance imaging of the brain and heart as well as echocardiography and retinal imaging. This will provide insight into the impact of post-partum blood pressure control on the maternal cardiovascular system and how this associates with blood pressure changes. Together, these studies will help refine future intervention strategies in this cohort of patients.
Detailed description
Summary of the Design ---------------------- The trial is a single centre, single blinded (the investigators will be unaware of which group the participants are allocated to), and randomised controlled study i.e. the group participants are put is allocated by chance. The study focuses on women who develop hypertensive disorders of pregnancy, which require ongoing treatment for blood pressure after birth at the time of discharge. These women will be randomised to one of two treatment arms: either usual care by GP/mid-wife/other NHS providers, or self -management of blood pressure. Women will be recruited from the John Radcliffe Hospital and this study will investigate the effectiveness of post-partum physician assisted self-management of blood pressure vs standard care over the first 6 (up to 9) months post-partum.
Trial Setting and participant profile
------------------------------------ The investigators aim to recruit 200 participants, of which 100 will be randomised to the intervention arm and 100 to the control arm. The intervention arm will comprise tele-monitored (remote) home blood pressure monitoring (including periods of home 24hr blood pressure monitoring) coupled to doctors overseeing medication self-management remotely. The control arm will receive 'standard' levels of NHS care from their GP and midwives and health visitors. All participants will be recruited from the Oxford Women's Centre at the John Radcliffe Hospital, which sees approximately 25 patients per month with hypertensive pregnancies (demonstrated in a local audit).
Trial participants --------------------- All participants will be females of childbearing age >18 years of age. Inclusion in the trial will require a clinician confirmed diagnosis of either gestational hypertension or pre-eclampsia as defined by NICE's latest guideline for this condition (NG 133), and the women must still require anti-hypertensive medication to control their blood pressure at the time of planned discharge.
Summary of the study visits
-------------------------- A flow chart of the proposed study visits can be seen in the protocol in section 9.7 and in appendix A of the protocol, which illustrates more clearly this textual description . The expected duration of participant involvement will be 6 (up to 9) months from enrolment to study completion and participants will be asked to attend four study visits after their pre-screening and enrolment: baseline, at 1 week, at 6 weeks and at 6-9 months. Although this study will only involve the four visits described above (outlined in appendix A) currently, further contact may be planned over the next 10 years to allow longitudinal follow up of this cohort. Details of the follow-up visits will be defined closer to the time and REC approval will be sought for any amendment/extension to this study to allow future contact. Additional consent will be sought from the participants to ensure they are happy to continue taking part.
Details of the study visits and procedures:
----------------------------------------- Both groups receive the same number of study visits, 4 visits for all participants.
Visit 1 (90 minutes) will take place in the first days after giving birth whilst participants remain on the post-natal ward in the Women's centre. The team will measure blood pressure, take some simple measurements e.g. weight, waist and hip circumference and scan their hearts (using ultra-sound just like they had of their babies). The team will then review the medical notes and blood tests and provide a questionnaire about lifestyle and diet, which can be completed later to shorten the visit. At the end of visit 1 participants will either be allocated to the intervention group or the control group. If allocated to the intervention group a separate member of the team will come and provide the participant with the blood pressure monitor (an OMRON EVOLV®) used for home monitoring. This team member will register and install the app on the participant's smartphone/tablet and teach the participant how to use it. They will therefore have plenty of time to practice with it whilst still in hospital.
Visits 2 and 3 (30 minutes) take place at weeks 1 and 6 weeks after discharge respectively and are to measure blood pressure, take some simple measurements e.g. waist, left arm and hip circumference, and to complete a brief questionnaire. These will be offered as a home visit, or as a visit to the Cardiovascular Clinical Research Facility (CCRF) at the John Radcliffe Hospital, depending on the women's preference, although based on prior experience it is expected most women will opt for home visits at this busy time in their lives. At the end of Visit 3 (week 6) there will be a 24 hour blood pressure monitor fitted, programmed to be silent to minimise disruption to the mum and the baby and the women will be provided with a stamped, addressed envelopes to post it back to CCRF. At the end of this visit, the team will run through the additional PIS relevant to the 4th visit again. This will allow participants to ask any questions about the longer final study visit up at the hospital, as the investigators are aware there is a lot to take in on the PIS and additional information sheet at the time of enrolment. The team will also call to discuss any further questions and plan child care for this longer visit in advance a few weeks prior to the 4th visit described below.
At 6-9 months there will be a slightly longer visit to CCRF in the John Radcliffe Hospital. Visit 4 (up to 4 hours) will involve measuring blood pressure again, doing another scan of the heart by ultra-sound, doing an MRI (magnet scan) of the heart and brain, and taking a blood test. There will also be a few other simple tests (not absolutely mandatory) but which are more exploratory secondary outcome measures for the study. These include: taking photos of the blood vessels in the back of the eye (retinal imaging, like an optician does), and doing some gentle exercise on a bike (akin to walking up a hill at a fast pace) during which the heart will be scanned to assess its response to exercise.
Each procedure that a participant will be asked to undergo during this study is summarised below in a little more detail: 1. Bed-side blood pressure measurement (10 minutes) Three blood pressure readings will be taken at intervals of 1 minute from the left arm using an automated blood pressure monitor (unless medical reason means the left arm cannot be used). This will require sitting at rest for 5 minutes prior to doing any measurements.
- Echocardiogram scan (15 minutes) The team will perform an ultrasound (echocardiogram/echo) of the heart. This is a safe and painless procedure that takes 15 minutes. The Participant will be asked to lie on a couch on theirleft side. A probe is placed on the chest and lubricating jelly is used so the probe makes good contact with the skin. Ultrasound waves then create images of the heart on the scanner monitor. A female sonographer/scanner will be provided wherever possible and if not available, a female chaperone will be provided.
- Vicorder® (Vascular Measures and Central Blood Pressures, 10 minutes): This involves lying flat on a cough and having two blood pressure cuffs fitted, one to the right arm and one around the right thigh. These are inflated and deflated three times at short intervals to acquire the readings. It is completely safe and painless.
- Lifestyle and physical activity questionnaire (25 minutes): The questionnaire combines validated questionnaires taken from previous studies. Information will be collected on factors that affect blood pressure including: smoking frequency, alcohol and salt intake, exercise and family history. Questionnaires can be completed either during a study visit or at a later date and posted back to the study team (prepaid envelopes will be provided).
- EQ-5D-5L Quality of Life questionnaire (5 minutes): Participants will be provided with an EQ-5D-5L questionnaire, which is a widely used and validated way of assessing quality of life at a set time-point. A trained study investigator will run through the structured questionnaire during the visit with the participant.
- MRI Heart and Brain (1 hour including break) The MRI scanner is shaped like a polo mint, the hole inside measuring about 60 centimetres wide. MRI is safe and non-invasive and does not involve any ionising radiation (x-rays). However, because they use a large magnet to work, MRI scans are not suitable for everybody. Because of this, participants will be asked pre-screening safety questions to help determine if participants are able to take part. More detail about the MRI scan is provided on the additional information sheet given to participants before the 4th study visit. This additional information sheet also provides more detail about the optional sub-study of having gadolinium given (a commonly used contrast drug for MRI) to acquire an extra few images in those women who are no longer breast-feeding at that time-point. Additional consent will be sought and obtained for this sub-study prior to the MRI scan being performed.
- Blood sampling (10 minutes) Blood samples will be collected (about 5 tablespoons (25mls) of blood). More detail is contained in the additional participant additional information sheet.
- Fitting of a home blood pressure monitor (5 minutes, to be worn for 24 hours) and activity monitor (5 minutes, to be worn for 7 days and nights) The monitor consists of a blood pressure cuff, which will be fitted on the left arm (right if a specific medical reason precludes use of the left). A small bag will also be provided that is worn around the waist or shoulders, in which the blood pressure monitor is placed. Participants will be shown how to re-attach the monitor e.g. after a bath or shower or should it fall off. The BP monitor will automatically inflate hourly during the day and every other hour at night to minimise inconvenience at this busy time in their lives. Participants will be asked to wear the blood pressure monitor for 24 hours and to keep a brief blood pressure monitoring diary and information sheet to detail time participants went to sleep/awoke and any periods of cardiovascular activity such as running for the bus/cycling to work. A stamped addressed envelope will be provided to return the device after use. The activity monitor is waterproof and shock-proof and will be worn continually on the wrist for one week and again a stamped addressed envelope will be provided to return the device after use.
- Retinal imaging (10 minutes) Photos will be taken of the back of the eyes just like at an optician. More information about this is provided on the additional PIS for the 4th study visit. To help keep personal information confidential, images will be 'de-identified' and assigned a study code. However, retinal images are unique so they can never be completely anonymous.
- Cardiopulmonary Exercise Testing (CPET) with exercise echo (30 minutes) This involves gentle cycling on a stationary bicycle and doing a short ultrasound (echocardiogram) of the heart whilst exercising. There will be real-time measurement of heart rate and blood pressure. More information about this is provided on the Additional PIS.
- Laser Speckle Tracking/Iontophoresis (15 minutes): this is an optional measure investigators will offer to 24 participants in each group of the trial. This will take an additional 15 minutes and is done twice; once at the baseline and once at the final/4th study visit in the 48 who agree. Participants will be asked to refrain from consuming caffeine (coffee, soft drinks, chocolate, etc.) for 4 hours prior to the forearm blood flow measurements. In this portion of the study, participants lay still in a bed. Two probes will be attached to the inner surface of the forearm. A special camera will be used to visualise blood flow in the skin of the forearm, which involves shining a red light on the skin. The investigators will use the probes to apply harmless solutions to the skin, while measuring the changes in the blood flow with the red light. This procedure causes no pain or discomfort.
The Intervention itself
------------------------- This next section only applies to participants in the intervention group and an additional intervention group information sheet will be provided for the participants allocated/randomised to this group in a written paper document as well as the information being available on the app and the study website. Women in this group will be asked to start measuring their blood pressure on the day of discharge from hospital using the OMRON EVOLV® monitor provided. This will mean taking 2 readings, 1 minute apart every morning after discharge. They will be asked to do this every morning, until they have had 5 consecutive days with blood pressure readings in the normal range (off medication). It is anticipated this will take 2-3 weeks following discharge based on our experience in our pilot study [SNAP-HT; REC 14/SC/1316].
After measuring the blood pressure, they will open up the POP-HT app on their smartphone/tablet, confirm it was them that took the blood pressure readings and click 'SYNC'. The app will then 'synchronise' with the OMRON EVOLV® monitor to upload the reading to the app and the secure study website hosted on the hospital's secure intranet (not the internet).
The smartphone/tablet will notify the participant if the readings are too high, too low or in the normal range. If they are high or low the app will ask them to repeat one more reading. If the reading is still high or low then the app will notify the participant and the specialist study doctors. The participant can then opt to receive a call from the study doctors to help adjust their own medication or they can choose see their own GP/mid-wife (further detailed information about this is available in the self-management information sheet).
Once a participant has 5 days in a row with readings in the normal range (off medication) they will be sent a notification/message reading "Thank you. Your blood pressure readings have all been normal since stopping treatment. Please change to once weekly readings for the remainder of the study." This will be until 6 months after the delivery of their baby/babies. The reason for the longer period of weekly monitoring is to ensure they do not have a late rise in your blood-pressure readings that requires further treatment.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Device: OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. |
| Control | No intervention | –The control arm will be managed as per usual NHS led care with assessment by their own health care professionals and adjustment of their medications as is needed. The BP of this group will be monitored and recorded at the same time-points and in the same manner as the intervention arm as will all other secondary outcome measures. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Participant is willing and able to give informed consent for participation in the trial.
- Female, aged 18 years or above.
- Clinician confirmed diagnosis of either gestational hypertension or pre-eclampsia defined by NICE NG 133
- Requiring anti-hypertensive medication at the point of discharge from secondary care.
- Participant has clinically acceptable laboratory results and clinical course post-partum with no other adverse complicating factor requiring prolonged admission post-partum that would make participation unfeasible as judged by the CI. Examples would include stroke sequalae, ongoing DIC, the baby/babies requiring prolonged NICU/SCBU admission of >1 week.
Key exclusion criteria (10 listed)
- Significant renal or hepatic impairment that would affect safe medication titration and adjustment as part of the trial, as deemed by the Investigator.
- Scheduled elective surgery (excluding caesarean sections) or other procedures requiring general anaesthesia during the trial.
- Participant with life expectancy of less than 6 months.
- Any other significant disease or disorder, which, in the opinion of the Investigator, may either, put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion. | Device | Intervention |
Primary outcome
Diastolic Blood pressure (BP)
Time frame: 6 months post-partum
24 hour average diastolic BP measured by 24 hour ambulatory BP monitoring (ABPM)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2021.
- Derived from this study: PubMed 42305089Cutler HR, Hanssen H, Hauser C, Streese L, Sattwika PD, Kitt J, McCourt A, Suriano K, Kenworthy Y, Frost A, Krasner S, Lewandowski AJ, Lapidaire W, Leeson P. Retinal Vascular Caliber: 6 to 12 Months and 15 to 25 Years Following Hypertensive Pregnancy. Hypertension. 2026 Aug;83(8):e27171. doi: 10.1161/HYPERTENSIONAHA.126.27171. Epub 2026 Jun 17.
- Derived from this study: PubMed 41490362Lapidaire W, Kitt J, Krasner S, Bateman PA, Cutler HR, Barr L, Frost A, Tucker K, Suriano K, Kenworthy Y, Milner G, Lacharie M, Mills R, Roman C, Mackillop L, Aye C, Cairns A, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Brain Volumes After Hypertensive Pregnancy and Postpartum Blood Pressure Management: A POP-HT Randomized Clinical Trial Imaging Substudy. JAMA Neurol. 2026 Feb 1;83(2):137-144. doi: 10.1001/jamaneurol.2025.5145.
- Derived from this study: PubMed 40905148Kitt J, Biasiolli L, Krasner S, Bateman PA, Cutler HR, Barr LC, Frost A, Tucker KL, Suriano K, Kenworthy Y, Lapidaire W, Lacharie M, Mills R, Roman C, Mackillop L, Aye CYL, Cairns AE, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Impact of Blood Pressure Self-Management on Vascular Remodeling After Hypertensive Pregnancy. Hypertension. 2025 Nov;82(11):1938-1947. doi: 10.1161/HYPERTENSIONAHA.125.24854. Epub 2025 Sep 4.
- Derived from this study: PubMed 40886083Cutler HR, Kitt J, Sattwika PD, Finnigan LEM, Estevez-Fernandez A, Kenworthy Y, Suriano K, Frost A, Krasner S, Johnson C, McCourt A, Mills R, Tucker K, Cairns A, Roman C, Aye C, Mackillop L, Thilaganathan B, Chappell LC, Raman B, Lewandowski AJ, Lapidaire W, Leeson P. Subclinical Postpartum Renal Structure After Hypertensive Pregnancy Disorders. Hypertension. 2025 Nov;82(11):1948-1958. doi: 10.1161/HYPERTENSIONAHA.125.25130. Epub 2025 Aug 31.
- Derived from this study: PubMed 37950919Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman PA, Suriano K, Kenworthy Y, McCourt A, Woodward W, Lapidaire W, Lacharie M, Santos M, Roman C, Mackillop L, Delles C, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial. JAMA. 2023 Nov 28;330(20):1991-1999. doi: 10.1001/jama.2023.21523.
- Derived from this study: PubMed 37950907Kitt J, Krasner S, Barr L, Frost A, Tucker K, Bateman PA, Suriano K, Kenworthy Y, Lapidaire W, Lacharie M, Mills R, Roman C, Mackillop L, Cairns A, Aye C, Ferreira V, Piechnik S, Lukaschuk E, Thilaganathan B, Chappell LC, Lewandowski AJ, McManus RJ, Leeson P. Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Substudy. Circulation. 2024 Feb 13;149(7):529-541. doi: 10.1161/CIRCULATIONAHA.123.067597. Epub 2023 Nov 11.
- Derived from this study: PubMed 35197335Kitt J, Frost A, Mollison J, Tucker KL, Suriano K, Kenworthy Y, McCourt A, Woodward W, Tan C, Lapidaire W, Mills R, Lacharie M, Tunnicliffe EM, Raman B, Santos M, Roman C, Hanssen H, Mackillop L, Cairns A, Thilaganathan B, Chappell L, Aye C, Lewandowski AJ, McManus RJ, Leeson P. Postpartum blood pressure self-management following hypertensive pregnancy: protocol of the Physician Optimised Post-partum Hypertension Treatment (POP-HT) trial. BMJ Open. 2022 Feb 23;12(2):e051180. doi: 10.1136/bmjopen-2021-051180.
- Individual participant dataSharing planned: No. Data will be made available, under certain circumstances, following data lock upon request to the study PI.
Related trials for Pre-Eclampsia
Recruiting
Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia
Postpartum Exercise, Cardiometabolic Health
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Severe Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app® in people with Pre-Eclampsia and Gestational Hypertension, run by University of Oxford at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diastolic Blood pressure (BP) (time frame: 6 months post-partum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04273854, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2021.